Molecular analysis of ganciclovir-resistant cytomegalovirus in renal transplant recipients with high viral load

Archives of Iranian Medicine

Volumn 19, Issue 10, 2016, Pages 700-703

  Sohrabi, Majid ^a   Behzadian, Farida ^b   Hosseini, Seied Mohammad Javad ^c   Lashini, Hadi ^c  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b MALEK ASHTAR UNIVERSITY OF TECHNOLOGY   (Iran)

^c BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cytomegalovirus (CMV); Solid organ transplant (SOP); UL54; UL97

Indexed keywords

GANCICLOVIR; ANTIVIRUS AGENT; DNA DIRECTED DNA POLYMERASE; GANCICLOVIR KINASE; PHOSPHOTRANSFERASE; UL54 PROTEIN, HUMAN HERPESVIRUS 5; VIRAL PROTEIN;

ARTICLE; CROSS-SECTIONAL STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; SEQUENCE ALIGNMENT; SERODIAGNOSIS; SPECTROPHOTOMETRY; VIRUS LOAD; ADVERSE EFFECTS; ANTIVIRAL RESISTANCE; DRUG EFFECTS; GENETICS; IRAN; MUTATION;

ANTIVIRAL AGENTS; CROSS-SECTIONAL STUDIES; CYTOMEGALOVIRUS; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; FEMALE; GANCICLOVIR; HUMANS; IRAN; KIDNEY TRANSPLANTATION; MALE; MUTATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); TRANSPLANT RECIPIENTS; VIRAL LOAD; VIRAL PROTEINS;

EID: 84991517495     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003; 9(9): 543-558.
2. Torres-Madriz G, Boucher HW. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis. 2008; 47(5): 702-711.
3. Reddy AJ, Zaas AK, Hanson KE, Palmer SM. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome. J Heart Lung Transplant. 2007; 26(12): 1286-1292.
4. Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis. 2002; 185(1): 20-27.
5. Le Page AK, Jager MM, Iwasenko JM, Scott GM, Alain S, Rawlinson WD. Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients. Clin Infect Dis. 2013; 56(7): 1018-1029.
6. Kim YJ, Boeckh M, Cook L, Stempel H, Jerome KR, Boucek R, Jr., et al. Cytomegalovirus infection and ganciclovir resistance caused by UL97 mutations in pediatric transplant recipients. Transpl Infect Dis. 2012; 14(6): 611-617.
7. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010; 23(4): 689-712.
8. Drew WL. Cytomegalovirus resistance testing: pitfalls and problems for the clinician. Clin Infect Dis. 2010; 50(5): 733-736.
9. Gilbert C, Boivin G. Human Cytomegalovirus Resistance to Antiviral Drugs. Antimicrob Agents Chemother. 2005; 49(3): 873-883.
10. Chou S, Marousek G, Li S, Weinberg A. Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. J Clin Virol. 2008; 43(1): 107-109.
11. Hakki M, Chou S. The biology of cytomegalovirus drug resistance. Curr Opin Infect Dis. 2011; 24(6): 605-611.
12. Boivin G, Goyette N, Rollag H, Jardine AG, Pescovitz MD, Asberg A, et al. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther. 2009; 14(5): 697-704.
13. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation.2010; 89(7): 779-795.
14. Chou S, Lurain NS, Weinberg A, Cai GY, Sharma PL, Crumpacker CS. Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. Antimicrob Agents Chemother. 1999; 43(6): 1500-1502.
15. Fillet AM, Auray L, Alain S, Gourlain K, Imbert BM, Najioullah F, et al. Natural polymorphism of cytomegalovirus DNA polymerase lies in two nonconserved regions located between domains delta-C and II and between domains III and I. Antimicrob Agents Chemother. 2004; 48(5): 1865-1868.
16. Chou S. Antiviral drug resistance in human cytomegalovirus. Transpl Infect Dis. 1999; 1(2): 105-114.
17. Tanaka K, Hori T, Yoto Y, Hatakeyama N, Yamamoto M, Suzuki N, Tsutsumi H. Human cytomegalovirus UL97 D605E polymorphism has a high prevalence in immunocompetent Japanese infants and children. Microbiol Immunol. 2011; 55(5): 328-330.
18. Chevillotte M, Ersing I, Mertens T, von Einem J. Differentiation between polymorphisms and resistance-associated mutations in human cytomegalovirus DNA polymerase. Antimicrob Agents Chemother. 2010; 54(12): 5004-5011.
19. Smith IL, Cherrington JM, Jiles RE, Fuller MD, Freeman WR, Spector SA. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis. 1997; 176(1): 69-77.
20. Erice A. Resistance of Human Cytomegalovirus to Antiviral Drugs. Clin Microbiol Rev.1999; 12(2): 286-297.
21. Chou S, Van Wechel LC, Lichy HM, Marousek GI. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob Agents Chemother.2005; 49(7): 2710-2715.
22. Zhou L, Fan J, Zheng SS, Ma WH. Prevalence of human cytomegalovirus UL97 D605E mutation in transplant recipients in China. Transplant Proc. 2006; 38(9): 2926-2928.
23. Gilbert C, Azzi A, Goyette N, Lin SX, Boivin G. Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet. Antimicrob Agents Chemother.2011; 55(9): 4019-4027.
24. Boivin G, Gilbert C, Gaudreau A, Greenfield I, Sudlow R Roberts NA. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J Infect Dis. 2001; 184(12): 1598-1602.
25. Boivin G, Goyette N, Gilbert C, Humar A, Covington E. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis. 2005; 7(3-4): 166-170.
26. Asberg A, Humar A, Jardine AG, Rollag H, Pescovitz MD, Mouas H, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant. 2009; 9(5): 1205-1213.
27. Madi N, Al-Qaser M, Edan R, Al-Nakib W. Clinical Utility of Viral Load in the Management of Cytomegalovirus Infection in Solid Organ Transplant Patients in Kuwait. Transplant Proc.2013; 47(6): 1802-1807.